Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION, STERILE
**2\. DOSAGE AND ADMINISTRATION** The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart. Due to netarsudil’s vasodilating properties, other eye drops should be administered before netarsudil. Eye ointments should be administered last.
OPHTHALMIC
Medical Information
**1\. INDICATIONS AND USAGE** RHOPRESSA (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension _\[see section 12 Clinical Studies_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
**4\. CONTRAINDICATIONS** Hypersensitivity to the active substance or to any of the excipients.
S01EX05
netarsudil
Manufacturer Information
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
Aerie Pharmaceuticals Ireland Limited
Active Ingredients
Documents
Package Inserts
Rhopressa Ophthalmic solution PI.pdf
Approved: July 4, 2023